Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate ...
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...
Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...
By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the ...
UK National Screening Committee rejects call from Olympic legend Sir Chris Hoy to offer PSA test to all men at higher risk of ...
PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...
Israeli PM Benjamin Netanyahu was taken to a Jerusalem hospital months after revealing prostate cancer treatment. Here’s what ...
Former President Joe Biden recently underwent surgery to remove skin cancer lesions and has been left with a large scar on his forehead, his office says. Biden’s representative, Kelly Scully, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results